Q
Q/C Technologies Inc.
Biotechnology: In Vitro & In Vivo Diagnostic Substances company
Key Metrics of Q/C Technologies Inc.
Revenue—FY 2023
Operating income−$17.1M▼ 12.0% YoY
Net profit−$4.0M▲ 73.7% YoY
Shareholders' equity$12.4M
Market cap$4.3MQCLS · $0.53
Competitors10identified
About Q/C Technologies Inc.
Sectors
Company details
- Founded
- 2014
- Listed
- Nasdaq: QCLS (since 2014)
Operational Areas of Q/C Technologies Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameQ/C Technologies Inc.
TickerQCLS
ExchangeNasdaq
CountryUnited States
SEC CIK0001321834
Listed since2014
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
QCLS · Nasdaq · SEC CIK 0001321834
Last price · 23 Oct 2026
$0.53
+3.50%
Market cap$4.3M
P/E—On FY 2023 diluted EPS
Volume51,270
SectorHealth CareBiotechnology: In Vitro & In Vivo Diagnostic Substances
Country · IPOUnited StatesListed 2014
QCLS share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Q/C Technologies Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.